Log in to search using one of your social media accounts:

 

Non-adherent spheres with multiple myeloma surface markers contain cells that contribute to the sphere formation and are capable of internalizing extracellular double-stranded DNA
We present phenotypic analysis of free-floating spheres derived from the bone marrow clonogenic aspirate of a multiple myeloma patient. Besides CD73/CD20+/CD45+/CD19dim B cells, these spheres encompass a special subpopulation of cells that can natively internalize extracellular double-stranded DNA and which contribute to the colony assembly. Various cell types found in the free-floating spheres communicate with each other by secreting distinct sets of cytokines. These spheres are capable of forming xenotrasplants upon grafting to immunodeficient NOD/SCID mice. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 22, 2016 Category: Hematology Authors: Evgeniya V. Dolgova, Ekaterina Ya Shevela, Tamara V. Tyrinova, Alexandra M. Minkevich, Anastasia S. Proskurina, Ekaterina A. Potter, Konstantin E. Orishchenko, Evgeniy L. Zavjalov, Sergey I. Bayborodin, Valeriy P. Nikolin, Nelly A. Popova, Natalia V. Pron Tags: Original Study Source Type: research

Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions
BCR-ABL1 tyrosine kinase inhibitors (TKIs) have dramatically transformed the treatment of patients with chronic myelogenous leukemia (CML). Given the impressive and sustained response to TKI therapy that the majority of treated patients with CML enjoy, recent studies have explored the potential to achieve treatment-free remission in select patients, which may allow these patients to escape the adverse clinical and financial effects associated with life-long TKI therapy. The results of multiple prospective trials have demonstrated that patients who maintain a deep molecular response for at least 2 years with TKI treatment m...
Source: Clinical Lymphoma, Myeloma and Leukemia - June 14, 2016 Category: Hematology Authors: Sheena Bhalla, Douglas Tremblay, John Mascarenhas Tags: Review Source Type: research

Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions
BCR-ABL1 tyrosine kinase inhibitors (TKIs) have dramatically transformed the treatment of patients with chronic myelogenous leukemia (CML). Given the impressive and sustained response to TKI therapy the majority of treated CML patients enjoy, recent studies have explored the potential to achieve treatment free remission (TFR) in select patients, which may allow these patients to escape the adverse clinical and financial effects associated with life-long TKI therapy. The results of multiple prospective trials have demonstrated that patients who maintain a deep molecular response for at least two years with TKI treatment may...
Source: Clinical Lymphoma, Myeloma and Leukemia - June 14, 2016 Category: Hematology Authors: S. Bhalla, D. Tremblay, J. Mascarenhas Tags: Review Article Source Type: research

Revised International Staging System Applied to Real World Multiple Myeloma Patients
Recently, the Revised International Staging System (RISS) was introduced for clinical use and is being adopted by the International Myeloma Working Group. The RISS was developed using data from patients enrolled in clinical trials. To assess the effect of RISS in real world patients, we studied 381 patients with newly diagnosed multiple myeloma and confirmed the role of RISS in unselected nonclinical trial patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Victor H. Jimenez-Zepeda, Peter Duggan, Paola Neri, Fariborz Rashid-Kolvear, Jason Tay, Nizar J. Bahlis Tags: Original Study Source Type: research

Diffuse Large B-Cell Lymphoma in the Elderly: Real World Outcomes of Immunochemotherapy in Asian Population
We evaluated the real-life treatment outcomes of elderly patients with diffuse large B-cell lymphoma from an Asian population. The medical records of 192 patients aged> 60 years who had received first-line immunochemotherapy were retrospectively analyzed. Elderly patients   (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Ja Min Byun, Jeong-Ok Lee, Beodeul Kang, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Soo-Mee Bang, Jong Seok Lee Tags: Original Study Source Type: research

Canonical Wnt/ β-Catenin Signaling Pathway Is Dysregulated in Patients With Primary and Secondary Myelofibrosis
Activation of the canonical wingless-related integration site (Wnt)/ β-catenin signaling pathway is associated with malignant transformation, development of fibrosis, and angiogenesis. We analyzed β-catenin mRNA expression in bone marrow of 29 patients with primary (PMF), 4 with secondary (SMF) myelofibrosis, and 16 control participants using quantitative real-time polymerase chain reaction (qRT PCR). β-Catenin expression is increased in PMF and SMF and might potentiate anemia. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Marko Lucijanic, Ana Livun, Cedna Tomasovic-Loncaric, Tajana Stoos-Veic, Vlatko Pejsa, Ozren Jaksic, Zeljko Prka, Rajko Kusec Tags: Original Study Source Type: research

Outcome of Second Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Lymphoblastic Leukemia
The outcome of patients with acute lymphoblastic leukemia relapsing after first allogeneic hematopoietic cell transplantation remains poor. A second transplant is a potential curative option for a subset of patients. Patients with relapse within the first year after allogeneic hematopoietic cell transplantation should preferably be enrolled in a clinical trial of novel therapies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Monzr M. Al Malki, Ibrahim Aldoss, Tracey Stiller, Ryotaro Nakamura, David S. Snyder, Stephen J. Forman, Vinod Pullarkat Tags: Original Study Source Type: research

Vaccination in Multiple Myeloma: Review of Current Literature
Multiple myeloma is a cancer of the immune system. Infection is a major cause of morbidity and mortality in patients with multiple myeloma. Some of these infections are preventable by vaccines available to the general population. However, little is known about the clinical effectiveness of these vaccines in patients with multiple myeloma, and the cellular and humoral immune response to vaccination has not been well characterized, especially in conjunction with modern myeloma therapies. The present report reviews the basics of multiple myeloma and the immune system, the available evidence on the immunologic response of pati...
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Andinet Alemu, John O. Richards, Martin K. Oaks, Michael A. Thompson Tags: Review Source Type: research

Continued Role of Splenectomy in the Management of Patients With Myelofibrosis
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by bone marrow fibrosis, cytopenias, extramedullary hematopoiesis, systemic symptoms, splenomegaly, and evolution to acute myeloid leukemia. Patients with polycythemia vera (PV) and those with essential thrombocythemia (ET) can progress to MF (post-PV or post-ET MF). Complications related to splenomegaly include mechanical symptoms (pain, early satiety, diarrhea, and bloating), manifestations of portal hypertension, and cellular sequestration resulting in exacerbation of existing cytopenias. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Daniel Aruch, Myron Schwartz, John Mascarenhas, Marina Kremyanskaya, Carrie Newsom, Ronald Hoffman Tags: Case Report Source Type: research

Anaplastic Multiple Myeloma: An Aggressive Variant With a Poor Response to Novel Therapies
Anaplastic multiple myeloma (AMM) is a very rare and aggressive morphologic variant of multiple myeloma with a historically poor prognosis.1 The term “anaplastic myeloma” is used to describe a plasma cell malignancy involving immature plasma cells of pleomorphic morphology with high-grade transformation and extramedullary involvement with large, poorly differentiated cells.1-3 Anaplastic morphology can be present at the initial diagnosis or c an appear later in the disease course.4-6 Historically, this disease has been very resistant to chemotherapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Nischala Ammannagari, Kimberly Celotto, Vishala Neppalli, Kelvin Lee, Sarah A. Holstein Tags: Case Report Source Type: research

Survival of Secondary Central Nervous System Lymphoma Patients in the Rituximab Era
In a review of 14 studies, the incidence of central nervous system (CNS) relapse ranged from 2.3% to 10% of patients with non-Hodgkin lymphoma (NHL; excluding acute lymphoblastic leukemia/lymphoblastic lymphoma and Burkitt lymphoma), with an overall risk of CNS relapse of 4.7%.1 Indolent lymphomas such as follicular lymphoma and mantle cell lymphoma do not spread to the brain as frequently as do the high-grade lymphomas such as acute lymphoblastic leukemia/lymphoblastic lymphoma and Burkitt lymphoma (2.8% and 24.4%, respectively). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Megan M. Herr, Nimish A. Mohile, Paul M. Barr, Edwin van Wijngaarden, Edward B. Brown, David Q. Rich Tags: Case Report Source Type: research

Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment With Tyrosine Kinase Inhibitors
To evaluate the risk of second malignancy (SM) during treatment with tyrosine kinase inhibitors (TKIs), a retrospective study was designed among chronic myeloid leukemia (CML) patients. The result suggested that patients with CML treated with TKIs had the higher relative incidence of SM compared with the expected incidence among the general Chinese population. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Xiu-Feng Yin, Jing-Han Wang, Xia Li, Meng-Xia Yu, Zhi-Xin Ma, Jie Jin Tags: Original Study Source Type: research

What to Do With Success? The Optimist ’s Creed in Relapsed Hodgkin Lymphoma
Checkpoint inhibitors have demonstrated remarkable efficacy in patients with chemotherapy-resistant Hodgkin lymphoma. However, it remains unclear whether these impressive agents have curative potential or whether relapse and death will eventually occur. In the present review, we discuss the options for a therapeutic dilemma that is likely to occur with increasing frequency, what to do for a patient with Hodgkin lymphoma who is responding to the checkpoint inhibitors? We discuss the 4 most likely considered options: continuation of checkpoint blockade, cessation of therapy with potential retreatment, transplantation, and ch...
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Amir K. Issa, Jason R. Westin Tags: Perspective Source Type: research

Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation
Reconstitution of the immune system after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is important in transplant outcomes. We retrospectively analyzed the data from 70 patients who had undergone allo-HSCT with the lymphocyte subset results. Also, the association between the lymphocyte subset counts and early complications and outcomes after allo-HSCT was analyzed. The natural killer cell counts after allo-HSCT were predictive of acute graft-versus-host disease, nonrelapse mortality, and survival. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Seo Yeon Kim, Hyewon Lee, Mi-Soon Han, Hyoeun Shim, Hyeon-Seok Eom, Boram Park, Sun-Young Kong Tags: Original Study Source Type: research

Canonical Wnt/ β-Catenin Signaling Pathway Is Dysregulated in Patients With Primary and Secondary Myelofibrosis
Activation of the canonical wingless-related integration site (Wnt)/ β-catenin signaling pathway is associated with malignant transformation, development of fibrosis, and angiogenesis. We analyzed β-catenin mRNA expression in bone marrow of 29 patients with primary (PMF), 4 with secondary (SMF) myelofibrosis, and 16 control participants using quantitative real-time polymerase chain reaction (qRT PCR). β-Catenin expression is increased in PMF and SMF and might potentiate anemia. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Marko Lucijanic, Ana Livun, Cedna Tomasovic-Loncaric, Tajana Stoos-Veic, Vlatko Pejsa, Ozren Jaksic, Zeljko Prka, Rajko Kusec Tags: Original Study Source Type: research

What to Do With Success? The Optimist ’s Creed in Relapsed Hodgkin Lymphoma
Checkpoint inhibitors have demonstrated remarkable efficacy in patients with chemotherapy-resistant Hodgkin lymphoma. However, it remains unclear whether these impressive agents have curative potential or whether relapse and death will eventually occur. In the present review, we discuss the options for a therapeutic dilemma that is likely to occur with increasing frequency, what to do for a patient with Hodgkin lymphoma who is responding to the checkpoint inhibitors? We discuss the 4 most likely considered options: continuation of checkpoint blockade, cessation of therapy with potential retreatment, transplantation, and ch...
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Amir K. Issa, Jason R. Westin Tags: Perspective Source Type: research

Outcome of Second Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Lymphoblastic Leukemia
The outcome of patients with acute lymphoblastic leukemia relapsing after first allogeneic hematopoietic cell transplantation remains poor. A second transplant is a potential curative option for a subset of patients. Patients with relapse within the first year after allogeneic hematopoietic cell transplantation should preferably be enrolled in a clinical trial of novel therapies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Monzr M. Al Malki, Ibrahim Aldoss, Tracey Stiller, Ryotaro Nakamura, David S. Snyder, Stephen J. Forman, Vinod Pullarkat Tags: Original Study Source Type: research

Diffuse Large B-Cell Lymphoma in the Elderly: Real World Outcomes of Immunochemotherapy in Asian Population
We evaluated the real-life treatment outcomes of elderly patients with diffuse large B-cell lymphoma from an Asian population. The medical records of 192 patients aged> 60 years who had received first-line immunochemotherapy were retrospectively analyzed. Elderly patients 
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Ja Min Byun, Jeong-Ok Lee, Beodeul Kang, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Soo-Mee Bang, Jong Seok Lee Tags: Original Study Source Type: research

Anaplastic Multiple Myeloma: An Aggressive Variant With a Poor Response to Novel Therapies
Anaplastic multiple myeloma (AMM) is a very rare and aggressive morphologic variant of multiple myeloma with a historically poor prognosis.1 The term “anaplastic myeloma” is used to describe a plasma cell malignancy involving immature plasma cells of pleomorphic morphology with high-grade transformation and extramedullary involvement with large, poorly differentiated cells.1-3 Anaplastic morphology can be present at the initial diagnosis or can appear later in the disease course.4-6 Historically, this disease has been very resistant to chemotherapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Nischala Ammannagari, Kimberly Celotto, Vishala Neppalli, Kelvin Lee, Sarah A. Holstein Tags: Case Report Source Type: research

Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation
Reconstitution of the immune system after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is important in transplant outcomes. We retrospectively analyzed the data from 70 patients who had undergone allo-HSCT with the lymphocyte subset results. Also, the association between the lymphocyte subset counts and early complications and outcomes after allo-HSCT was analyzed. The natural killer cell counts after allo-HSCT were predictive of acute graft-versus-host disease, nonrelapse mortality, and survival. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Seo Yeon Kim, Hyewon Lee, Mi-Soon Han, Hyoeun Shim, Hyeon-Seok Eom, Boram Park, Sun-Young Kong Tags: Original Study Source Type: research

Continued Role of Splenectomy in the Management of Patients With Myelofibrosis
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by bone marrow fibrosis, cytopenias, extramedullary hematopoiesis, systemic symptoms, splenomegaly, and evolution to acute myeloid leukemia. Patients with polycythemia vera (PV) and those with essential thrombocythemia (ET) can progress to MF (post-PV or post-ET MF). Complications related to splenomegaly include mechanical symptoms (pain, early satiety, diarrhea, and bloating), manifestations of portal hypertension, and cellular sequestration resulting in exacerbation of existing cytopenias. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Daniel Aruch, Myron Schwartz, John Mascarenhas, Marina Kremyanskaya, Carrie Newsom, Ronald Hoffman Tags: Case Report Source Type: research

Revised International Staging System applied to Real World Multiple Myeloma Patients
A variety of validated prognostic markers for Multiple Myeloma have been described to help inform clinical practice. Recently, a robust system has been introduced for clinical use and is being adopted by the IMWG-Revised International Staging System (RISS). The RISS was developed using data from patients enrolled in clinical trials and consequently its utility is less clear in unselected Myeloma patients. All consecutive NDMM patients managed and followed at Tom Baker Cancer Center (TBCC) from 01/2004 to 10/2015 were included in this study. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Victor H. Jimenez-Zepeda, Peter Duggan, Paola Neri, Fariborz Rashid-Kolvear, Jason Tay, Nizar J. Bahlis Tags: Original Study Source Type: research

Diffuse Large B-cell Lymphoma in The Elderly: Real-world Outcomes of Immunochemotherapy in Asian Population
We evaluated real-life treatment outcomes of elderly diffuse large B cell lymphoma (DLBCL) from an Asian population. Medical records of 192 patients over 60 years old treated with first-line immunochemotherapy were retrospectively analyzed. Elderly patients (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Ja Min Byun, Jeong-Ok Lee, Beodeul Kang, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Soo-Mee Bang, Jong Seok Lee Tags: Original Study Source Type: research

Canonical Wnt/β-catenin signaling pathway is dysregulated in patients with primary and secondary myelofibrosis
Activation of Wnt/β-catenin signaling pathway is associated with malignant transformation, development of fibrosis and angiogenesis. We analyzed β-catenin mRNA expression in bone marrows of 29 patients with primary (PMF), four with secondary myelofibrosis (SMF) and 16 controls using qRT-PCR. Β-catenin expression is increased in both PMF and SMF and might potentiate anemia. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Marko Lucijanic, Ana Livun, Cedna Tomasovic-Loncaric, Tajana Stoos-Veic, Vlatko Pejsa, Ozren Jaksic, Zeljko Prka, Rajko Kusec Tags: Original Study Source Type: research

Outcome of Second Allogeneic Hematopoietic Cell Transplantation (AlloHCT2) in Patients with Acute Lymphoblastic Leukemia (ALL)
The outcome of patients with ALL relapsing after AlloHCT1 is poor. A second transplant remains a potential curative option in a subset of patients. Patients who relapse within the first year post AlloHCT1 should preferably be enrolled in a clinical trial of novel therapies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Monzr M. Al Malki, Ibrahim Aldoss, Tracey Stiller, Ryotaro Nakamura, David S. Snyder, Stephen J. Forman, Vinod Pullarkat Tags: Original Study Source Type: research

Vaccination in Multiple Myeloma: Review of Current Literature
This article reviews the basics of multiple myeloma and the immune system, the available evidence on immunologic response of multiple myeloma patients following vaccination, and current practice recommendations regarding specific vaccines. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Andinet Alemu, John O. Richards, Martin K. Oaks, Michael A. Thompson Tags: Review Article Source Type: research

The Continued Role of Splenectomy in the Management of Patients with Myelofibrosis
We report, however, that splenectomy remains an effective and safe therapy for those with continued spleen related mechanical symptoms refractory to ruxolitinib and for patients with severe cytopenias that precludes ruxolitinib use. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Daniel Aruch, Myron Schwartz, John Mascarenhas, Marina Kremyanskaya, Carrie Newsom, Ronald Hoffman Tags: Case Report Source Type: research

Anaplastic Multiple Myeloma: An aggressive variant with poor response to novel therapies
Anaplastic multiple myeloma is a very rare and aggressive morphologic variant of multiple myeloma with a historically poor prognosis.1 The term anaplastic myeloma is used to describe a plasma cell malignancy involving immature plasma cells of pleomorphic morphology with high grade transformation and extramedullary involvement with large, poorly differentiated cells. 1-3 Anaplastic morphology may be present at time of initial diagnosis or may appear later in the course of disease.4-6 Historically, this disease has been very resistant to chemotherapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Nischala Ammannagari, Kimberly Celotto, Vishala Neppalli, Kelvin Lee, Sarah A. Holstein Tags: Case Report Source Type: research

Survival of Secondary Central Nervous System Lymphoma Patients in the Rituximab Era
In a review of 14 studies, central nervous system (CNS) relapse ranged from 2.3% to 10% in non-Hodgkin lymphoma (NHL) patients (excluding acute lymphoblastic leukaemia/lymphoma (ALL/LBL) and Burkitt lymphoma (BL)) with an overall risk of CNS relapse of 4.7%.1 Indolent lymphomas such as follicular lymphoma and mantle cell lymphoma do not spread to the brain as frequently as the high grade lymphomas such as ALL/LBL and BL (2.8% and 24.4%, respectively).2 (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Megan M. Herr, Nimish A. Mohile, Paul M. Barr, Edwin van Wijngaarden, Edward B. Brown, David Q. Rich Tags: Case Report Source Type: research

Incidence of second malignancies of chronic myeloid leukemia during treatment with tyrosine kinase inhibitors
In order to evaluate the risk of second malignances(SM) during treatment with tyrosine kinase inhibitors(TKIs), a retrospective study is designed among chronic myeloid leukemia (CML) patients. The result suggested that patients with CML treated with TKIs had the higher relative incidence of SM when compared with the expected incidence among the general Chinese population. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Xiu-Feng Yin, Jing-Han Wang, Xia Li, Meng-Xia Yu, Zhi-Xin Ma, Jie Jin Tags: Original Study Source Type: research

What to do with success? The optimist’s creed in relapsed Hodgkin lymphoma
Checkpoint inhibitors have demonstrated remarkable efficacy in patients with chemotherapy resistant Hodgkin lymphoma. However, it remains unclear if these impressive agents have curative potential, or if relapse and death will eventually occur. In this review, we discuss the options for a therapeutic dilemma which is likely to occur with increasing frequency, what to do for a Hodgkin lymphoma patient who is responding the checkpoint inhibitors? We discuss the four most likely considered options: continuation of checkpoint blockade, cessation of therapy with potential re-treatment, transplantation, and chimeric antigen rece...
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Amir Issa, Jason Westin Tags: Perspective Source Type: research

Post-transplantation NK Cell Count: A Predictor of Acute GVHD and Survival Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation
Reconstitution of the immune system after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is important in transplant outcomes. We retrospectively analyzed data from 70 patients who underwent allo-HSCT with lymphocytes subset (LST) results. And the association between LST counts with early complications and outcomes after allo-HSCT was analyzed. NK cell counts after allo-HSCT were predictive of acute GVHD, NRM and survival. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Seo Yeon Kim, Hyewon Lee, Mi-Soon Han, Hyoeun Shim, Hyeon-Seok Eom, Boram Park, Sun-Young Kong Tags: Original Study Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 31, 2016 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 31, 2016 Category: Hematology Source Type: research

Optimizing the Use of TKIs in the Management of Chronic Myelogenous Leukemia
The objective of this study was to evaluate the performance of clinicians on multiple aspects of CML management and to target any identified proficiency gaps. The results demonstrated the benefits of s serial learning approach as participants who completed multiple activities achieved the greatest clinical performance gains from baseline. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 8, 2016 Category: Hematology Authors: Karyn Ruiz-Cordell, Steven Haimowitz, Linda Gracie-King, Deborah Middleton Tags: Original Study Source Type: research

Clinical Implications of CD30 Expression in Aggressive B-cell Lymphomas
FDA approval of Brentuximab for treatment of CD30+ relapsed/refractory lymphomas initiated research focused on CD30 expression in lymphomas. Several studies examined CD30 expression in subsets of DLBCL. In our study we have expanded this research by studying CD30 expression in other types of aggressive B-cell lymphomas, including Burkitt lymphomas, high grade Follicular Lymphomas, FL3/DLBCL, DLBCL type PTLDs and PMBLs. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 8, 2016 Category: Hematology Authors: Jozef Malysz, Patrick Erdman, Jeremy Klapper, Junjia Zhu, Michael Creer, Michael G. Bayerl Tags: Original Study Source Type: research

Cyclophosphamide and bortezomib with prednisone or dexamethasone for the treatment of relapsed and refractory multiple myeloma
Clinical trials of the combination of cyclophosphamide, bortezomib and steroids in relapsed/refractory myeloma have shown promising results, but there is little information about real-world outcomes. We retrospectively reviewed the results of weekly CyBorP(D) in 96 patients treated off study. The overall response rate was 69%; median PFS was 16.2 months. Toxicity was mild with low rates of myelosuppression and neuropathy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 8, 2016 Category: Hematology Authors: Donna E. Reece, Young Trieu, Esther Masih-Khan, Eshetu G. Atenafu, Christine Chen, Anca Prica, Rodger Tiedemann, Suzanne Trudel, Vishal Kukreti Tags: Original Study Source Type: research

Validation and Utility of the Free Light Chain Assay in Pleural Effusions of Patients With Multiple Myeloma
Although multiple myeloma (MM) is a bone marrow disorder, ≤ 20% of patients will ultimately develop extramedullary disease that can involve virtually any organ.1,2 Pleural effusions are also a relatively uncommon occurrence in MM (incidence of 6%)1 and are most often complications of infection or dysproteinemia, such as nephritic syndromes, congestive heart failure secondary to amyloidosis, or mediastinal lymphatic obstruction. The findings from case reports and larger studies have suggested myelomatous pleural effusions (MPEs) will be present in only 1% to 2% of MM patients,3,4 and the diagnosis of MPE is ominous,...
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Thomas U. Marron, Matthew G. Hanna, Lakshmi Ramanathan, Ajai Chari Tags: Case Report Source Type: research

Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
Relapse is the major cause of allogeneic hematopoietic stem cell transplantation failure in high-risk Philadelphia chromosome-positive (Ph+) leukemia. Post-transplant maintenance therapy is a promising strategy. We found maintenance imatinib and dose-reduced newer generation tyrosine kinase inhibitors to be feasible and generally well tolerated. This approach might reduce the incidence of relapse and improve the outcomes after allogeneic hematopoietic stem cell transplantation for high-risk Ph+ leukemia. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Zachariah DeFilipp, Amelia A. Langston, Zhengjia Chen, Chao Zhang, Martha L. Arellano, Fuad El Rassi, Christopher R. Flowers, Vamsi K. Kota, Zaid Al-Kadhimi, Rachel Veldman, Anand P. Jillella, Sagar Lonial, Edmund K. Waller, Hanna J. Khoury Tags: Original Study Source Type: research

Fluorescent In Situ Hybridization Monitoring and Effect of Detected Early Responses in the Outcome of Patients With Chronic Phase Chronic Myeloid Leukemia: A Report From a Latin American Country
Our aim was to assess the routine use of fluorescent in situ hybridization in the monitoring of chronic phase chronic myeloid leukemia. We retrospectively analyzed data from 63 patients. The monitoring adherence assessment revealed better compliance rates compared with previous reports. Excellent correlation between fluorescent in situ hybridization and chromosome banding analysis was found. Achieving a complete cytogenetic response, assessed by fluorescent in situ hybridization, was an independent prognostic factor in the outcomes of patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Christianne Bourlon, Carlos Hernandez-Mata, Cesar Vargas-Serafín, María T. Bourlon, Elena Tuna-Aguilar, Alvaro Aguayo Tags: Original Study Source Type: research

Letter to the Editor
We read with interest the report by Subari et al1 in which they evaluated the difference in survival outcomes between therapy-related chronic myelomonocytic leukemia (CMML) and de novo CMML. They revealed that patients with therapy-related CMML had poorer survival than those with de novo CMML (median overall survival [OS], 11 vs. 20 months; P = .02). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Mohamed Abd El-Fattah Tags: Letter to the Editor Source Type: research

Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study
Imatinib has been the standard of care in chronic myelogenous leukemia for 15 years. Its optimal plasma concentration correlates with optimal disease response. We compared plasma concentrations in patients who switched from branded to generic imatinib. No statistical difference in achieved imatinib plasma concentrations was found, and the treatment response was maintained. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Alen Ostojic, Dubravka Sertic, Pavle Roncevic, Zinaida Peric, Paula Granic, Nikolina Matic, Sandra Basic-Kinda, Ranka Serventi-Seiwerth, Ivo Radman, Renata Zadro, Damir Nemet Tags: Original Study Source Type: research

Anti Myelin-Associated-Glycoprotein Antibody Peripheral Neuropathy Response to Combination Chemoimmunotherapy With Bendamustine/Rituximab in a Patient With Biclonal IgM κ and IgM λ: Case Report and Review of the Literature
Symptoms of peripheral neuropathy are very common, with conventional estimates of prevalence in the United States in the tens of millions. Approximately 10% of patients with a polyneuropathy of unknown cause have a coexistent monoclonal gammopathy. Many of these are incidental gammopathies, unrelated to the neuropathy. However, there are numerous entities in which the gammopathy induces the neuropathy, and is therefore the prime target for therapy (eg, amyloidosis, Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS), immunoglobulin [Ig]M deposition disease, etc). (Source: Clinical ...
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Alexandra Gomez, James E. Hoffman Tags: Case Report Source Type: research

Fluorescent in situ hybridization monitoring and impact of detected early responses in the outcome of CP-CML patients: a report of a Latin American country
Our aim was to assess the routine use of fluorescent in situ hybridization (FISH) in the monitoring of chronic phase chronic myeloid leukemia (CP-CML). We retrospectively analyzed data from 63 patients. The monitoring adherence assessment revealed better compliance rates compared to previous reports. Excellent correlation between FISH and chromosome banding analysis (CBA) was found. Achieving a complete cytogenetic response (CCyR), assessed by FISH, was an independent prognostic factor in the outcome of patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Christianne Bourlon, Carlos Hernandez-Mata, Cesar Vargas-Serafín, María T. Bourlon, Elena Tuna-Aguilar, Alvaro Aguayo Tags: Original Study Source Type: research

Comparison of branded and generics imatinib plasma concentrations in patients with chronic myelogenous leukemia – unicentric study
Imatinib has been the standard of care in chronic myelogenous leukemia for fifteen years. Its optimal plasma concentration correlates with optimal disease response. We compared plasma concentrations in patients who switched from branded to generic imatinib. No statistical difference in achieved imatinib plasma concentrations was found, and the treatment response was maintained. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Alen Ostojic, Dubravka Sertic, Pavle Roncevic, Zinaida Peric, Paula Granic, Nikolina Matic, Sandra Basic-Kinda, Ranka Serventi-Seiwerth, Ivo Radman, Renata Zadro, Damir Nemet Tags: Original Study Source Type: research

Anti Myelin-Associated-Glycoprotein (MAG) antibody peripheral neuropathy response to combination chemoimmunotherapy with Bendamustine - Rituximab in a patient with biclonal IgM kappa and IgM lambda gammopathy: Case report and review of the literature
Symptoms of peripheral neuropathy are very common, with conventional estimates of prevalence in the United States in the tens of millions. Approximately ten percent of patients with a polyneuropathy of unknown cause have a coexistent monoclonal gammopathy. Many of these are incidental gammopathies, unrelated to the neuropathy. However, there are numerous entities wherein the gammopathy induces the neuropathy, and is therefore the prime target for therapy (e.g. amyloidosis, POEMS, IgM deposition disease etc). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Alexandra Gomez, James E. Hoffman Tags: Case Report Source Type: research

Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120
We describe 3 patients with relapsed/refractory acute myeloid leukemia who developed clinically-apparent differentiation concurrent with clinical response during monotherapy with AG-120, a novel, oral inhibitor of mutant isocitrate dehydrogenase 1. Symptoms included marked leukocytosis and exuberant neutrophil recovery among other clinically-apparent constitutional manifestations. Awareness of the potential for differentiation syndrome with such inhibitors, and prompt identification and intervention, are essential to facilitate clinical resolution. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Birendra KC, Courtney D. DiNardo Tags: Original Study Source Type: research

Autologous stem cell mobilization in the age of plerixafor
Plerixafor is a potent stem cell mobilizing agent whose cost is prohibitive for routine use. In 277 consecutive patients, the addition of rescue plerixafor during suboptimal G-CSF mobilization or after prior failure of chemotherapy plus G-CSF, was associated with successful mobilization in 97.5% of patients with target collections achieved in 60% of lymphoma and 72% of myeloma patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Dennis L. Cooper, Erin Medoff, Natalie Patel, Julie Baker, Kathryn Pratt, Francine Foss, Stuart E. Seropian, Sarah Perreault, Yanyun Wu Tags: Original Study Source Type: research

Validation and utility of the free light chains assay in pleural effusions of patients with multiple myeloma
Although multiple myeloma (MM) is a bone marrow disorder, up to twenty percent of patients will ultimately develop extramedullary (EM) disease that can involve virtually any organ.1,2 Pleural effusions are also a relatively uncommon occurrence in MM (incidence of 6%)1, and are most often complications of infection or dysproteinemia such as nephritic syndromes, congestive heart failure secondary to amyloidosis, or mediastinal lymphatic obstruction. Case reports and larger studies suggest myelomatous pleural effusions (MPEs) to be present in only 1-2% of MM patients3,4, and the diagnosis of MPE is ominous, with a median life...
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Thomas U. Marron, Matthew G. Hanna, Lakshmi Ramanathan, Ajai Chari Tags: Case Report Source Type: research

Clinical features and treatment outcomes of patients with Necrobiotic Xanthogranuloma associated with monoclonal gammopathies
Necrobiotic xanthogranuloma (NXG) is a rare chronic granulomatous disorder of the skin associated with a monoclonal gammopathy. This is a single tertiary medical center retrospective study which describes the clinical features of 35 patients with NXG and monoclonal gammopathy as well as their subsequent disease course and response to treatment. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Larissa S. Higgins, Ronald S. Go, David Dingli, Shaji K. Kumar, S. Vincent Rajkumar, Angela Dispenzieri, Francis K. Buadi, Martha Q. Lacy, John A. Lust, Prashant Kapoor, Nelson Leung, Yi Lin, Taxiarchis V. Kourelis, Morie A. Gertz, Robert A. Kyle, Wilson Tags: Original Study Source Type: research